Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price8.95 USD
Fair value14.48
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Distribution8.81+1.6% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
BellRing Brands, Inc. holds its Distribution at $8.95. The statistical read favours the sellers, held for 24 days.
As held on the ledger · 2026-09-21
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 24 days
Price at the screen
$8.95
Valuation
6.30 trailing · 6.77 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.50
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
115.23%
Below 33%
Interest-bearing debt is 115.2% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
29.48%
Below 49%
Money owed to the company is 29.5% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. A 61.8% margin of safety to the base estimate.
Third-party analyst targets: 12 covering, consensus Buy. The average target sits +62% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Protein Shakes Sell But Growth Stays Flat
Walk into any gym or supermarket aisle and the Premier Protein bottles stand out, yet the company behind them grows revenue at just 2 percent a year. At a forward multiple of 9 times earnings the valuation looks undemanding, and the ethical screen clears, but our opportunity rating stays at none because thin 7 percent margins and an unknown moat leave little room for durable outperformance.
Analysts still lean buy with a $13 median target, yet the modest growth and lack of visible competitive edge make this a pass for us. A defensive label does not automatically create value when sales barely move and the business offers no clear pricing power.
Low growth in packaged foods often signals a value trap rather than a bargain, especially when earnings can slip if input costs or shelf space shift. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BRBR trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-23Distribution$10.99-9.3%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 9.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14.
2026-07-23Distribution$12.12+37.6%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 37.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14.
2026-07-18Distribution$8.81+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14.
2026-07-03Distribution$8.81+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$8.81Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
